The total return over the past 12 months is -43.67% vs. +16.94% for the S&P 500. So far it's up -62.31% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (43.67%) | (49.29%) | (57.40%) | (50.38%) | N/A | N/A |
| Total Return CAGR | (43.67%) | (49.29%) | (57.40%) | (50.38%) | N/A | N/A |
| Revenue CAGR | (177.27%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Outlook Therapeutics, Inc. (OTLK)
| Year | Start price | End price | OTLK Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.58 | $0.60 | (62.31%) | +14.51% | (76.82%) |
| 2025 | $1.89 | $1.58 | (16.40%) | +17.72% | (34.12%) |
| 2024 | $7.88 | $1.89 | (76.02%) | +24.89% | (100.91%) |
| 2023 | $21.60 | $7.88 | (63.52%) | +26.19% | (89.71%) |
| 2022 | $27.20 | $21.60 | (20.59%) | (18.17%) | (2.42%) |
| 2021 | $26.00 | $27.20 | +4.62% | +28.74% | (24.12%) |
| 2020 | $11.80 | $26.00 | +120.34% | +18.37% | +101.97% |
| 2019 | $80.00 | $11.80 | (85.25%) | +31.22% | (116.47%) |
| 2018 | $208.00 | $80.00 | (61.54%) | (4.56%) | (56.98%) |
| 2017 | $481.60 | $208.00 | (56.81%) | +21.70% | (78.51%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
